Methotrexate, uracil and tegafur, and leucovorin chemotherapy for patients with breast cancer in progression after high-dose chemotherapy with peripheral blood progenitor cell transplant : A phase II study

Thirty-four patients with metastatic breast cancer (MBC) who had progression of disease after high-dose chemotherapy (HDCT) with peripheral blood progenitor cell support (PBPC) had methotrexate, uracil and tegafur (UFT), and leucovorin (MUL) therapy administered: methotrexate administered intramuscu...

Full description

Saved in:

Bibliographic Details
Published in:	American journal of clinical oncology Vol. 23; no. 6; pp. 617 - 621
Main Authors:	MARTIN, Miguel, CASADO, Antonio, MACIAS, Jose Antonio, GARCIA-CARBONERO, Iciar, GARCIA-SAENZ, Jose Angel, ORUEZABAL, Mauro, MANRIQUE, Isabel, DIAZ-RUBIO, Eduardo
Format:	Journal Article
Language:	English
Published:	Hagerstown, MD Lippincott Williams & Wilkins 01-12-2000
Subjects:	Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Breast Neoplasms - drug therapy Breast Neoplasms - pathology Chemotherapy Hematopoietic Stem Cell Transplantation Humans Leucovorin - administration & dosage Medical sciences Methotrexate - administration & dosage Middle Aged Neoplasm Metastasis Pharmacology. Drug treatments Salvage Therapy Survival Analysis Tegafur - administration & dosage Uracil - administration & dosage Antineoplastic agent Human Drug combination Toxicity Treatment efficiency Fluoropyrimidine derivatives Tegafur Hematopoietic cell Calcium folinate Malignant tumor Mammary gland diseases Chemotherapy Treatment Immunotherapy Phase II trial Tumor progression Graft Combined treatment Mammary gland Salvage treatment Methotrexate High dose Uracil Progenitor cell
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!